Navigation Links
Drug increases hemoglobin in Myelodysplastic Syndrome

Patients with Bone marrow disorder Myelodysplastic Syndrome (MDS), treated with 500 mcg of Aranesp (Darbepoetin alfa) for every three weeks found to improve the hemoglobin content in 70% of patients. //The new drug Aranesp is manufactured by Amgen Biotech, which conducted a Phase II trial with 200 low-risk MDS patients who were administered with 500 mcg of Aranesp every three weeks. MDS is a pre-leukemia stage in which the bone marrow does not produce the required blood cells. MDS is associated with abnormal blood counts resulting in anemia (low red blood cell count), Neutropenia (low white blood cell count) and Thrombocytopenia (low blood platelet count).

Professor Janice Gabrilove, Medical Oncologist, Mount Sinai School of Medicine, New York said that, “During the course of their disease, the majority of MDS patients develop clinically significant anemia, which can lead to fatigue and the need for red blood cell transfusions currently, there are no recombinant erythropoietic products approved for the treatment of anemia in MDS patients."

The Phase II trial was conducted for 13 weeks and their erythroid response was evaluated by measuring the hemoglobin, 70 percent of patients had an erythroid response, with 49 percent classified as major response , 67% of patients achieved the target hemoglobin level of 11 g/dL. 19% in the erythropoietin-naive group had at least one transfusion during the 13-week observation period. In the group previously treated with an erythropoietic agent (n= 59), 44 percent experienced an erythroid response, with 24 percent classified as major. Forty-five percent of patients achieved the target hemoglobin level of 11 g/dL, and 29 percent had at least one transfusion.

Source: Eurekalert.


'"/>




Page: 1

Related medicine news :

1. Human gene number increases
2. Stress response increases suicide risk
3. Sleep apnoea increases post-operative risks
4. Vaginosis increases risk of miscarriage
5. Serotonin increases stroke risk
6. Depression increases heart attacks
7. Excess vitamin A increases fracture risk
8. High vitamin A increases risk of hip fractures
9. Less sleep increases mortality rates
10. Smoking during pregnancy increases risk of cleft palate
11. Obesity increases health costs
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:2/12/2016)... ... February 12, 2016 , ... Fixed ... p.m. – 3:00 p.m. EST, http://www.fdanews.com/fixeddosecombination , Fixed ... pharmaceutical products, garnering increased attention from all stakeholders in the development of new ...
(Date:2/12/2016)... ... February 12, 2016 , ... T.E.N., a ... closed for the ISE Southeast Awards 2016. Finalists and winners of the ISE® ... Southeast Executive Forum and Awards Gala on March 15, 2016 at the Westin ...
(Date:2/12/2016)... ... ... Fisher House Foundation Chairman and CEO Kenneth Fisher joined Governor Brian Sandoval, ... Scott Bensing, and Peggy Kearns Director, VA Southern Nevada Healthcare System yesterday to dedicate ... be the first Fisher House in Nevada, and will provide free lodging for families ...
(Date:2/12/2016)... ... , ... Erlanger Agency has announced a new partnership in its ongoing community ... on the fight against breast cancer, fundraising for a local woman named Carmen, who ... Carmen is a loving single mother of two boys who also serves as caregiver ...
(Date:2/12/2016)... ... February 12, 2016 , ... For Coast Dental dentist Everet ... RDH, and dental assistant Terrell Moore shortly before 7 a.m. to volunteer at Friday’s ... professionals, donating their time and skills to help hundreds of uninsured and underinsured people ...
Breaking Medicine News(10 mins):
(Date:2/11/2016)... , Feb. 11, 2016 ... Companion Diagnostics in Personalized Medicine and Cancer Therapy. ... - High-Growth Diagnostic Testing Markets. - Key Diagnostic ... - Molecular Diagnostics in Genetic Testing. - ... Diagnostics Markets. - Over-the-Counter Diagnostic Products World Markets. ...
(Date:2/11/2016)... 2016  Kindred Biosciences, Inc. (NASDAQ: KIN ), ... lives of pets, today announced the submission to FDA ... Drug Application (NADA) for Zimeta™ (dipyrone injection, KIND-012).  Positive ... Zimeta for the control of pyrexia (fever) in horses ... --> --> The Chemistry, Manufacturing, and ...
(Date:2/11/2016)... 2016  NOIT™ Research LLC, a private, leading-edge autism ... campaign to assist needy families in obtaining one of ... between February 10, 2016 and March 31, 2016, the ... The NOIT is an auditory stimulus that plays a ... skills. Beth Shier , NOIT Research ...
Breaking Medicine Technology: